Opinion

Video

Persistence and Discontinuation Rates for Non-Statin Therapies in ASCVD

Author(s):

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPSAQ Cardiology, CACP,Kate Cabral, PharmD, BCCP, FACC, FCCP

Clinical insights on how real-world treatment persistence and discontinuation rates compare between the various non-statin therapies and the factors that contribute to these differences.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
Related Content
Atrial fibrillation (AF) -- Image credit: ibreakstock | stock.adobe.com
July 14th 2025

FDA Approves Expanded Labeling of Farapulse PFA System for Persistent Atrial Fibrillation

Gillian McGovern, Associate Editor
COBRRA Trial Results Raise Questions About VTE Management
July 15th 2025

COBRRA Trial Results Raise Questions About VTE Management

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPSAQ Cardiology, CACP Aislinn Antrim, Managing Editor
Highlights From NLA 2025: Early LDL-C Reduction and Emerging Therapies
July 9th 2025

Highlights From NLA 2025: Early LDL-C Reduction and Emerging Therapies

Jennifer D. Goldman, PharmD, CDE, BC-ADM, FCCP Alana Hippensteele, Lead Editor
An Overview of Intravenous Iron in Heart Failure and the FAIR-HF2 Trial
July 1st 2025

An Overview of Intravenous Iron in Heart Failure and the FAIR-HF2 Trial

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPSAQ Cardiology, CACP Aislinn Antrim, Managing Editor
Medical heart cardiology concept | Image Credit: Peera | stock.adobe.com
Published: July 7th 2025 | Updated: July 7th 2025

Integrity Concerns in Ticagrelor Trials Challenge Clinical Confidence

Danielle Valletti, Assistant Editor
Cardiomyopathy (ATTR-CM) -- Image credit: Dzmitry | stock.adobe.com
July 1st 2025

Pharmacists Have a Crucial Role Helping Patients With ATTR-CM Navigate Treatment With Tafamidis

Gillian McGovern, Associate Editor Jennifer Goldman, PharmD, CDES, BC-ADM, FCCP